All of this is true. I think what I was referring to was that there was limited uptake by HIV providers when the product first launched but after those few patients started showing CXCR4 MVC was quickly sidelined. That happened in conjunction with what you were saying, which is other a RVs Came out with efficacy, side effect, profiles, resistance, profiles, and some offered as single tablet regiment making MVC even less desirable as a treatment option. Oh, and then there were those blackbox warnings.